---
title: "Bicara Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285934017.md"
datetime: "2026-05-11T11:35:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285934017.md)
  - [en](https://longbridge.com/en/news/285934017.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285934017.md)
---

# Bicara Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.93, missing the estimate of USD -0.6508.

EBIT: As of FY2026 Q1, the actual value is USD -64.33 M.

#### Cash, Cash Equivalents and Marketable Securities

As of March 31, 2026, Bicara Therapeutics Inc. held $539.8 million in cash, cash equivalents, and marketable securities, an increase from $414.8 million as of December 31, 2025. The company received approximately $161.8 million in net proceeds from an oversubscribed public offering during the first quarter of 2026.

#### Research and Development Expenses

Research and development expenses for the first quarter of 2026 were $47.5 million, up from $34.3 million for the first quarter of 2025.

#### General and Administrative Expenses

General and administrative expenses increased to $12.7 million for the first quarter of 2026, compared to $7.5 million for the same period in 2025.

#### Net Loss

Bicara Therapeutics Inc. reported a net loss of - $56.2 million for the first quarter of 2026, which is an increase from the - $36.8 million net loss reported in the first quarter of 2025.

#### Other Financial Details (in thousands)

-   **Total Operating Expenses:** $60,242 for Q1 2026, up from $41,788 for Q1 2025.
-   **Loss from Operations:** - $60,242 for Q1 2026, compared to - $41,788 for Q1 2025.
-   **Interest Income:** $4,083 for Q1 2026, down from $5,014 for Q1 2025.
-   **Net Loss Before Income Taxes:** - $56,159 for Q1 2026, compared to - $36,774 for Q1 2025.
-   **Income Tax Expense:** - $52 for Q1 2026, compared to - $72 for Q1 2025.
-   **Net Loss per Share (basic and diluted):** - $0.93 for Q1 2026, compared to - $0.68 for Q1 2025.
-   **Weighted-Average Common Shares Outstanding (basic and diluted):** 60,717,041 for Q1 2026, compared to 54,456,515 for Q1 2025.
-   **Total Comprehensive Loss:** - $56,697 for Q1 2026, compared to - $36,846 for Q1 2025.
-   **Total Stock-Based Compensation Expense:** $5,858 for Q1 2026, compared to $3,451 for Q1 2025.

#### Balance Sheet (in thousands)

-   **Total Current Assets:** $544,915 as of March 31, 2026, compared to $422,053 as of December 31, 2025.
-   **Total Assets:** $553,599 as of March 31, 2026, compared to $430,994 as of December 31, 2025.
-   **Total Current Liabilities:** $39,340 as of March 31, 2026, compared to $28,949 as of December 31, 2025.
-   **Total Liabilities:** $39,641 as of March 31, 2026, compared to $29,542 as of December 31, 2025.
-   **Total Stockholders’ Equity:** $513,958 as of March 31, 2026, compared to $401,452 as of December 31, 2025.

#### Operational Highlights

Bicara Therapeutics Inc. made progress in its FORTIFI-HN01 pivotal trial for 1L HPV-negative R/M HNSCC and plans to initiate a randomized clinical study for ficerafusp alfa in Q3 2026. The company also announced executive changes, with Bill Schelman becoming Chief Medical Officer and Chris Sarchi appointed as Chief Commercial Officer.

#### Outlook / Guidance

Bicara Therapeutics Inc. expects its current cash, cash equivalents, and marketable securities to fund operations into the first half of 2029. The company anticipates substantial enrollment in the FORTIFI-HN01 pivotal trial by year-end 2026, enabling an interim analysis in mid-2027 for potential accelerated approval. A new randomized study for ficerafusp alfa is planned to initiate in Q3 2026, with data presentations at ASCO 2026 and in H2 2026 for other solid tumors.

### Related Stocks

- [BCAX.US](https://longbridge.com/en/quote/BCAX.US.md)

## Related News & Research

- [Wedbush Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)](https://longbridge.com/en/news/286216781.md)
- [Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data](https://longbridge.com/en/news/286469142.md)
- [Are Wall Street Analysts Predicting Brown-Forman Stock Will Climb or Sink?](https://longbridge.com/en/news/286932286.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [Elis: Disclosure of the number of shares forming the capital and of the total number of voting rights as of 30 04 2026](https://longbridge.com/en/news/286770212.md)